After studying data from non-clinical studies, clinical trials, post-marketing surveillance, and medical literature, the committee found that NAION is a very rare side effect of GLP-1
Second, the 0.25 mg initiation step is deliberately sub-therapeutic for weight loss
Before propensity score matching, the semaglutide group included 127, 352, and 498 patients across the three BMI subgroups, respectively, while the control group included 11,277, 8,722, and 6,870 patients
Mounjaro posed the most significant risk, with users facing more than a 50% higher likelihood of serious GI complications compared to SGLT-2 inhibitors like Januvia and Farxiga
Most patients notice weight loss within 4 to 8 weeks of starting semaglutide, according to the STEP 1 trial
The Liver Finally, the liver has the ability to make sugar through a process called gluconeogenesis